Clinical trials: Prostate Cancer, open to volunteers
Prostate Cancer Metastatic Disease
Efficacy and Tolerability of Low-Dose Enzalutamide in Prostate Cancer
Prostate cancer is the most common cancer in men in the United States and the second leading cause of cancer-related mortality in males.
- Trial name
- LODE (NCT06718647)
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Monica Boitano
Prostate Cancer, Prostate Adenocarcinoma
Whole Versus Partial Gland Boost During Prostate SBRT
The purpose of this randomized phase II trial is to compare dose escalation of the prostate versus the dominant intra-prostatic lesion in a reduced fraction radiation therapy regimen.
- Trial name
- NCT07574489
- Testing
- Prostate stereotactic body radiotherapy with whole gland boost, Prostate stereotactic body radiotherapy with DIL boost
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of Nebraska
Prostate Cancer
Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer
To test the hypothesis that intensive cholesterol lowering (iCL) therapy has anti-tumor immune modulating activity, the investigators will conduct an open-label, single-arm phase II trial in prostate cancer patients who are in…
- Trial name
- NCT06437574
- Testing
- Vytorin, Ezetimibe
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Cedars-Sinai Medical Center
Prostate Cancer, MRI
NEWPROMRI-PATHWAY - A New Prostate Magnetic Resonance Imaging (MRI) Pathway
Prostate cancer is the second most common cancer in men worldwide. The demand for magnetic resonance imaging (MRI) to diagnose and manage prostate cancer is continually growing.
- Trial name
- NEWPROMRI (NCT06672926)
- Where
- United Kingdom
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- University Hospitals of North Midlands NHS Trust
Prostate Cancer
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
The purpose of this research is to gather information on the safety and effectiveness of combining focal prostate ablation therapy ((aka Focal Therapy, a surgical procedure) and androgen deprivation therapy (hormone therapy).
- Trial name
- NCT05790213
- Testing
- Androgen Deprivation Therapy (ADT), Focal prostate ablation (focal therapy)
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Chicago
Prostate Cancer
Comparing PSMA PET/CT and MRI-RSI for Finding and Outlining Tumors Inside the Prostate in Men With Newly Diagnosed Prostate Cancer
The detection and delineation of the intraprostatic tumor burden plays a crucial role in the personalized treatment of primary prostate cancer.
- Trial name
- PRIDE2-PC (NCT07568613)
- Testing
- MRI, 18F-PSMA1007 PET-CT, MR-guided TRUS Prostate biopsy
- Where
- Cyprus
- Volunteers
- 50 people
- Sponsor
- German Oncology Center, Cyprus
mCRPC
Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）
This study is to evaluate the safety, and preliminary antitumor activity of TYK-00540 combined with Enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy
- Trial name
- NCT07104643
- Testing
- TYK-00540, Enzalutamide
- Where
- China
- Volunteers
- 48 people
- Sponsor
- TYK Medicines, Inc
Metastatic Castration-resistant Prostatic Neoplasms
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in…
- Trial name
- KLK2-comPAS (NCT07164443)
- Testing
- Pasritamig, Best Supportive Care (BSC), JNJ-87189401
- Where
- 176 sites in United States, Australia and 15 more
- Volunteers
- 1,203 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
The Principal Investigator's (PI) working hypothesis is that the PI can utilize the high predictive value of 18F-DCFPyl PSMA to identify clinically significant tumors in patients who will undergo brachytherapy, as well as areas…
- Trial name
- NCT03861676
- Testing
- Focal brachytherapy with PSMA PET imaging, (18F)DCFPyL
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer, Prostate Cancer (Adenocarcinoma)
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
The goal of this clinical trial is to learn if fezolinetant can treat hot flashes (vasomotor symptoms) in men with prostate cancer undergoing androgen deprivation therapy.
- Conditions
- Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Disease, Prostate Cancer Recurrent
- Trial name
- Fezo-ADT (NCT06957691)
- Testing
- fezolinetant - reference formulation
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Shehzad Basaria, M.D.
Metastatic Castration-resistant Prostate Cancer
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
The purpose of this study is to evaluate whether high-dose testosterone followed by targeted radioligand therapy (TRT) is effective in treating metastatic castration resistant prostate cancer.
- Trial name
- NCT07476001
- Testing
- Testosterone cypionate (Tc), ADT with Luteinizing hormone-releasing hormone (LHRH) analog, PSMA-617
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer Patients, Sexual Dysfunctions
Dyadic STEP-SexPCare for Sexual Health in Chinese Prostate Cancer Survivors and Their Female Partners
This pilot feasibility randomized controlled trial will evaluate the feasibility, acceptability, safety, and preliminary effects of Dyadic STEP-SexPCare, a culturally tailored, nurse-led psychosexual programme for Hong Kong…
- Trial name
- STEP-SexPCare (NCT07829367)
- Testing
- Dyadic STEP-SexPCare, Standard Survivorship Care
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Prostatic Neoplasms, Castration-Resistant
Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.
The objectives of the study are to analyze the results obtained in survival, safety and quality of life after the combination of SBRT plus second-generation antiandrogen in patients diagnosed with metastatic castration-resistant…
- Trial name
- OLIGORESIST (NCT07717268)
- Testing
- Xtandi, Zytiga® (Abiraterone Acetate), SBRT
- Where
- 15 sites in Spain
- Volunteers
- 51 people
- Sponsor
- Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Prostate Cancer, Biochemical Recurrence
Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)
ARES is a multicenter, single-arm, phase 2 trial to evaluate the efficacy and safety of ADT in combination with apalutamide as an adjuvant regimen for patients with high risk of recurrence after radical prostatectomy.
- Conditions
- Prostate Cancer, Biochemical Recurrence, High Risk
- Trial name
- ARES (NCT05778097)
- Testing
- Apalutamide 60mg Tab, Androgen deprivation therapy(ADT)
- Where
- 3 sites in China
- Volunteers
- 103 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer (Adenocarcinoma)
Prostate Androgen Response Investigation Using a Stratification BIOmarker; Predicting Prostate Cancer Downstaging by Neoadjuvant Darolutamide With PCAI ImmunoScore
The PARIS-BIO study evaluates whether a novel genomic biomarker, the PCAI ImmunoScore, can predict the response to neoadjuvant treatment with Darolutamide in patients with high-risk localized or locally advanced prostate cancer.
- Trial name
- PARIS-BIO (NCT07617272)
- Testing
- Darolutamide, Radical prostatectomy
- Where
- 2 sites in Sweden
- Volunteers
- 100 people
- Sponsor
- Region Stockholm
Prostate Adenocarcinoma, Prostate Cancer
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
This phase II trial studies the side how well hyperpolarized carbon C 13 pyruvate (HP C-13 pyruvate) magnetic resonance imaging (MRI) works in monitoring patients with prostate cancer on active surveillance who have not received…
- Trial name
- NCT03933670
- Testing
- Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Spectroscopic Imaging, MRI Ultrasound Fusion Guided Biopsy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Preoperative Semaglutide Prior to Radical Prostatectomy
In this exploratory, single-arm, nonrandomized trial, the impact of the preoperative utilization of the glucagon-like peptide-1 (GLP-1) receptor agonist (RA) semaglutide prior to radical prostatectomy in participants with…
- Trial name
- NCT07727473
- Testing
- Semaglutide 2.4 mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Banner Health
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- NEXUS-01 (NCT06465069)
- Testing
- LY4052031, Pembrolizumab
- Where
- 40 sites in United States, Australia and 6 more
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Kidney Cancers, Bladder Cancer
Development of a Preclinical 3D Vascularized and Perfused Tumoroid Model in Oncology and Urology Developed From Patient Tumors (Kidney, Bladder, and Prostate Cancers)
This is a study : Single-center Prospective Translational Based on data and blood samples. In this context, the aim is to collect approximately 10 ml of blood from each patient included in the 3D tumoroid development project.
- Conditions
- Kidney Cancers, Bladder Cancer, Prostate Cancer
- Trial name
- 3DBlood (NCT07820566)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Prostate Cancer, Lower Urinary Tract Symptoms
HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer
To determine if holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms (LUTS) and/or urinary retention alters the treatment course for patients concurrently diagnosed with prostate…
- Trial name
- HOLEP-RTPC (NCT03802851)
- Testing
- Holmium Laser Enucleation of Prostate (HoLEP)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Kansas Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.